Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04918524

The Clinical Features and Pregnancy Outcomes of CTD Patients

Connective tissue disease (CTD) is a common group of autoimmune diseases, mainly including systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) , and so on. APS is caused by autoimmune disorders that cause recurrent miscarriage, thrombosis, and thrombocytopenia, and often secondary to connective tissue diseases such as SLE. Undifferentiated connective tissue disease (UCTD) is currently considered to be an independent disease in the classification of CTD. And women of childbearing age who suffer UCTD is more common than that in other definite CTDs. Therefore, the impact of the disease flare and the influence of medicine on pregnancy and lactation are important for these patients who may suffer high-risk of abnormal pregnance.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

About this study

Objective: To study the risk factors of poor pregnancy outcomes in CTD patients, and evaluate impact of different therapies on the maternal and fetal health.

Methods: Our department and Shanghai Gothic Network Technology Co.Ltd. jointly established the chronic disease management of CTD patients during pregnancy and lactation by using Smart System of Disease Management (SSDM). With this platform, patients in pregnancy can consult with rheumatologists face to face and follow-up regularly.

Follow-up: Consultation and followup will be scheduled every 4 weeks from confirmed pregnancy until delivery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women who meet the following inclusion criteria will be eligible to participate in the study:
  • Age between 20-45 years;
  • Diagnosed with APS: patients meet the Sydney classification criteria;
  • Diagnosed with UCTD: at least one presence of auto-antibodies, including antinuclear antibody (ANA), anti-extractable nuclear antigen (ENA) antibodies, anti-doublestranded DNA (ds-DNA) antibody, antiphospholipid antibody(aPL), and non-criteria aPL (NC-aPL), with at least one symptoms or signs suggesting connective tissue disease(CTD) , while not fulfilling any classification criteria of a defined CTD.
  • Participate voluntarily in this study, willing to use medication and follow-up according to treatment plan, and sign informed consent.

Exclusion criteria

  • Women who meet any of the following criteria will be excluded from the study:

1.Any known etiology of previous pregnancy loss:

  • Known paternal, maternal or embryo chromosome abnormality.
  • Maternal endocrine dysfunction: corpus luteal insufficiency; polycystic ovarian syndrome; premature ovarian failure (follicle stimulating hormone, FSH ≥20uU/L in follicular phase);
  • hyperprolactinemia; diabetes mellitus; other hypothalamic pituitary-adrenal axis abnormality
  • Maternal anatomical abnormality: uterine malformation; Asherman syndrome; cervical incompetence; uterine fibrosis more than 5 cm.Vaginal infection.
  • Any known severe cardiac, hepatic, renal, hematological or endocrinal diseases:
  • Any active infection: Active infection including V aricella zostervirus(VZV), human immunodeficiency virus (HIV), Human papillomavirus (HPV),syphilis or tuberculosis.
  • Allergic to prednisone, hydroxychloroquine, low-molecular-weight heparin or aspirin.

4.Disease history as follows:

  • Past history of digestive ulcers or upper gastrointestinal hemorrhage.
  • Past history of malignancy.
  • Past history of epilepsia or psychotic disorders.

5.Women have been diagnosed with Systemic lupus erythematosus

  • Women who disagree or cannot complete pregnancy and follow-up after delivery.

Treatment and study plan

Prednisone

Drug

5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response

Other names: Pred

Hydroxychloroquine

Drug

100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.

Other names: HCQ

Aspirin

Drug

100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.

Other names: Asp

low molecular weight heparin Enoxaparin

Drug

40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.

Other names: LMWH

Primary outcomes

  1. Live birth rate

    Time frame: After 28 weeks of gestation

    Percentage of all patients that lead to live birth after 28 weeks of gestation

Secondary outcomes

  1. Early fetal loss

    Time frame: within 10 weeks of gestation

    Spontaneous pregnancy loss within 10 weeks of gestation

  2. Late fetal loss

    Time frame: after 10 weeks of gestation

    Spontaneous pregnancy loss after 10 weeks of gestation

  3. Stillbirth

    Time frame: after 20 weeks of gestation

    Spontaneous pregnancy loss after 20 weeks of gestation

  4. Preterm delivery

    Time frame: between 28 and 37 weeks of gestation

    Live birth before 37 weeks of gestation

  5. Low-weight birth

    Time frame: after 28 weeks of gestation

    newborns with low weight (<2500g)

  6. Premature rupture of membranes

    Time frame: after 28 weeks of gestation

    the number of participants complicated with premature rupture of membranes

  7. Placental abruption

    Time frame: after 28 weeks of gestation

    the number of participants complicated with placental abruption

  8. Fetal growth retardation (FGR)

    Time frame: after 12 weeks of gestation

    weight below the 10th percentile for the gestational age

  9. Number of participants with low amniotic fluid during pregnancy

    Time frame: after 12 weeks of gestation

    the number of participants whose B-ultrasound indicates low amniotic fluid during pregnancy

  10. Number of participants with abnormal S / D values during pregnancy

    Time frame: after 12 weeks of gestation

    the number of participants whose B-ultrasound indicates abnormal S / D values during pregnancy

  11. Number of participants with placental hematoma during pregnancy

    Time frame: during pregnancy, an average of 10 months

    the number of participants whose B-ultrasound indicates placental hematoma during pregnancy

  12. Eclampsia

    Time frame: after 20 weeks of gestation

    New-onset hypertension after 20 weeks of gestation, with or without proteinuria > 300mg/24h, with or without any organ damage with seizures

  13. Gestational diabetes

    Time frame: through study completion, an average of 10 months

    the number of participants who were diagnosed with gestational diabetes

  14. Gestational hypertension

    Time frame: through study completion, an average of 10 months

    the number of participants who were diagnosed with gestational hypertension

  15. Number of participants with placental infarction

    Time frame: at delivery

    the number of participants whose placenta with infarction.

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Qilu Hospital of Shandong University

Other

Registry information

Official study title

The Clinical Features and Pregnancy Outcomes of Patients With Connective Tissue Disease :a Prospective Cohort Study

Important dates

Study start
2018
Primary completion
2025
Study completion
2026
First posted
Jun 9, 2021
Registry last updated
Nov 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.